Caris Life Sciences, Inc., a leading AI TechBio company specializing in precision medicine, reported a significant increase in revenue for the fiscal year 2025, reaching $812.0 million compared to $412.3 million in 2024. This growth was primarily driven by a substantial rise in molecular profiling services revenue, which soared to $766.7 million, representing a 119.6% increase year-over-year. However, pharma research and development services revenue experienced a decline, decreasing by 28.2% to $45.3 million. Despite the revenue surge, the company still reported a net loss of $68.1 million, a notable improvement from the $281.9 million loss in the previous fiscal year.
The company's financial performance was significantly influenced by the increased adoption of its MI Profile platform and Caris Assure services. Clinical case volumes for MI Profile reached 170,300, while Caris Assure volumes climbed to 29,000. The launch of MI Cancer Seek, an FDA-approved companion diagnostic, also contributed to the revenue growth. The company's strategic focus on expanding its clinico-genomic datasets and leveraging AI/ML algorithms played a crucial role in enhancing its precision medicine solutions.
Key operational developments included the commercial launch of MI Cancer Seek and the continued expansion of the Caris Assure platform. The company also focused on building its commercial organization and strengthening relationships with biopharma partners. As of December 31, 2025, Caris Life Sciences had 1,846 employees, reflecting its continued investment in human capital to support its growth initiatives. The company's laboratory infrastructure, with facilities in Phoenix and Tempe, Arizona, also played a critical role in supporting its operations.
Looking ahead, Caris Life Sciences plans to continue driving adoption of its tissue-based profiling solutions and expanding its blood-based profiling offerings. The company also aims to leverage its platform to provide solutions to biopharma companies and capitalize on the potential of Caris Detect, its WGS-based solution in development. While the company anticipates continued growth, it also acknowledges the competitive landscape and the need to navigate regulatory and reimbursement challenges. The company's future performance will depend on its ability to execute its strategies and adapt to the evolving precision oncology market.
About Caris Life Sciences, Inc.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.